Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Progressive Digital Media Group PLC       GB00B1GCQP32

PROGRESSIVE DIGITAL MEDIA GROUP PLC
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlobalData : Global Clostridium difficile infections market to approach $1.7 billion by 2026

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/24/2017 | 01:29pm CET

The Clostridium difficile infections (CDIs) space across the seven major markets of the US, France, Germany, Italy, Spain, the UK and Japan, is set to grow from just under $630 million in 2016 to almost $1.7 billion by 2026, representing a compound annual growth rate of 10.2%, according to research and consulting firm GlobalData.

The company's latest report states that the major drivers of this growth include the projected launch of prophylactic options for the prevention of C. difficile, microbiological approaches for the treatment of recurrent CDIs (rCDIs), and novel antibiotics positioned to reduce the rate of disease recurrence relative to the standard of care.

Thomas Moore, Ph.D., Healthcare Analyst for GlobalData, explains: 'Current treatment options are generally limited to antibiotics, with orally administered vancomycin considered the standard of care. Some pharmaceutical companies are developing non-antibiotic alternatives in the hope that they will provide an attractive option for physicians. For example, Merck's monoclonal antibody, Zinplava (bezlotoxumab), was approved by the FDA in October 2016, and is the first non-antibiotic option indicated to treat CDIs.'

Several investigational products aim to leverage the clinical potential of fecal microbiota transplants (FMT) to create a drug that lowers the rate of recurrence for patients recovering from CDIs. Seres Therapeutics' SER-109 and Rebiotix's RBX2660 are both FMT-derived therapies that aim to provide an alternative for physicians with strong clinical efficacy and safety data. Both have completed Phase II clinical efficacy trials, and will be positioned to target patients with rCDI.

Moore continues: 'Companies are also developing prophylactic interventions for the prevention of CDIs, some of which GlobalData anticipates will launch during the forecast period. Sanofi Pasteur's toxoid vaccine ACAM-CDIFF is currently undergoing Phase III clinical trials and is likely to be the first CDI prophylactic product to market. Two other vaccines, Pfizer's PF-06425090 and Valneva's VLA84, are also on track to launch within the forecast period.

'Although current antibiotic treatment options are effective at curing existing infections, they leave patients susceptible to recurrence. In this way, manufacturers should take note of the unmet need for interventional products that reduce the risk of recurrence for patients recovering from CDIs. Despite the fact that Zinplava will partially satisfy this need, it will still remain significant for the duration of the forecast period.'

- Information based on GlobalData's report: OpportunityAnalyzer: Clostridium difficile Infections - Opportunity Analysis and Forecasts to 2026.

GlobalData plc published this content on 24 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 24 July 2017 11:29:07 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PROGRESSIVE DIGITAL MEDIA
02/16GLOBALDATA : Majority of healthcare providers beef up security architecture to p..
PU
02/16GLOBALDATA : Canada leads the way in equities, observes GlobalData
AQ
02/15GLOBALDATA : Active millennials are being priced out of skiing and golf holidays
PU
02/15GLOBALDATA : Majority of oncology clinical trials in China failed to meet enrolm..
PU
02/14GLOBALDATA : Over $58.5B to be spent on North Sea oil & gas by 2020
AQ
02/14GLOBALDATA : 60% of the worlds megacities will be located in Asia by 2025, says ..
PU
02/14VALENTINE’S DAY 2018 : Consumers say Tesco does the best job at promoting ..
PU
02/14VALENTINE’S DAY 2018 : Cost conscience consumers to cut fine dining on Val..
PU
02/14GLOBALDATA : Indian banks can do more to make open banking obvious path to prosp..
PU
02/13GLOBALDATA : Need for supportive care in oncology will increase during the next ..
PU
More news
Financials ( GBP)
Sales 2017 118 M
EBIT 2017 -
Net income 2017 -
Debt 2017 33,4 M
Yield 2017 1,41%
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales 2017 5,01x
Capi. / Sales 2018 -
Capitalization 559 M
Income Statement Evolution
Managers
NameTitle
Michael Thomas Danson Chief Executive Officer
Bernard Anthony Cragg Chairman
Graham Charles Lilley Chief Financial Officer & Secretary
Peter Martin Harkness Independent Non-Executive Director
Murray Legg Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
PROGRESSIVE DIGITAL MEDIA GROUP PLC791
S&P GLOBAL INC9.82%47 438
RELX N.V.-13.62%43 140
RELX-15.70%43 136
THOMSON REUTERS CORP-8.03%28 495
EQUIFAX-3.28%13 695